An observational study in NAFLD, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-16.
Sponsored by Tanta University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University — 6 open to participants now, 8 under way, 4 of them phase 3. Non-alcoholic Fatty Liver Disease · Tanta University.
Among the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, this one is the only one that started in 2024, is the only observational one, and was the 9th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →6 of the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University are open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18–65
Tanta University · Sites in Egypt
Ages 18+ · Healthy volunteers
Tanta University · Sites in Egypt
Ages 18–60
Tanta University · Sites in Egypt
Ages 18–60
Tanta University
Ages 18+
By country, each count listing its studies:
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 5 · Phase 4 2
First in 2019; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 152 across 391 observational studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 58 across the 12 interventional studies, 500 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Non-alcoholic Fatty Liver Disease by Tanta University that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07900100Phase 3Tanta UniversityEvaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients. | 2027-06-20 |
| NCT07900087Phase 3Tanta UniversityEvaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients | 2027-08-01 |
| NCT06863376Tanta UniversityEvaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients | 2027-03-20 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of liver disease worldwide. The global burden of NAFLD is about 30% of the population, With a higher prevalence in Egypt about 47.5 %. The prevalence increases significantly with the presence of type 2 diabetes and obesity.
NAFLD is commonly associated with metabolic dysfunction and the development of cardiovascular disease. However, the NAFLD definition excludes other causes. It is not correlated with metabolic dysfunction and cardiovascular risk, so in 2020, the term metabolic-dysfunction-associated fatty liver disease (MAFLD) was suggested to replace the term NAFLD.
The nomenclature change was partly related to the stigma associated with the term NAFLD. As the words "alcoholic" and "fatty" were considered stigmatizing. A recent global survey showed that 26% of patients (57% in the USA and 7% in MENA) felt stigmatized relating to overweight/obesity and 8% of patients (22 % in the USA and 3% in MENA) felt stigmatized by the term NAFLD. While 34% and 38% of physicians considered the words "non-alcoholic" and "fatty" stigmatizing, respectively.
There is a discrepancy between the different regions of the world and between patients and providers regarding the perception of NAFLD/ MAFLD stigma. This study aims to assess the perception and stigmatization of various diagnostic terms (fatty liver, NAFLD \& MAFLD) among Egyptian patients and physicians. Also, to assess the impact of stigma on the quality of life and the motivations and barriers for lifestyle modification which is the cornerstone of NAFLD/MAFLD management.
This cross-sectional study will be carried out in collaboration between the Tropical Medicine Department and Public Health Department, Tanta University Hospitals. A questionnaire in both digital and written forms targeting patients with NAFLD/NASH and physicians treating NAFLD/NASH patients in Egypt.
Type of study:
Prospective, cross-sectional survey.
Duration of study:
Study will be carried out from May 2024 to August 2024 or until the target number is reached (about 500 subjects).
Target subjects:
The questionnaire will target a convenience sample of NAFLD/NASH patients and physicians treating NAFLD/NASH patients (about 500 subjects).
The questionnaire will be written and digital in both Arabic and English versions.
Methodology:
After designing the questionnaire, it will be discussed with other experts in the field, validity and reliability will be assessed and a pilot study will be done.
After an informed consent subject will answer a designed questionnaire either written or digital. 2 phases will be done The questionnaire will be divided into 3 sectors Sector 1: Demographic data: questions about [age, sex, residence, educational level, occupation (subspecialty), workplace] for all participants.
Sector 2: Socioeconomic level determination mainly for population :( Socio-economic data will be gathered through questions asking about the number of family members, number of rooms in the apartment, level of education, occupation, and cost per month).
Sector 3: the main work includes questions for patients: (patient awareness of NAFLD before diagnosis, presence and severity of liver fibrosis, presence of comorbidities, the diagnostic term they use to describe their disease, have they disclosed their condition to family or friends, have they experienced stigmatization or discriminations due to their disease and how frequently, how they feel about the words fatty, alcoholic, and metabolic, have they avoided or missed a visit with their physician due to NAFLD, patients concerns about the disease and its progression, barriers, and motivations for lifestyle modifications).
For physicians :(their clinical experience in NAFLD and the number of NAFLD/NASH patients they see per month, what terms they think are considered stigmatizing to their patients "fatty, non-alcoholic, overweight/obese, metabolic associated", does their patients feel discrimination due to their disease, would the name change help their patients, causes of frustration and discomfort when treating NAFLD patients, their opinion of what are the barriers and motivations for lifestyle modifications in their patients)
Ethical considerations:
A written or digital informed consent form authorizing the collection of this data was signed by all subjects The study will be approved by the Ethical Committee of Faculty of Medicine Tanta University.
The risks to the participants and measures needed to minimize these risks:
Adequate provisions to maintain the privacy of participants and confidentially of data are as follows:
The endpoint of this study:
Assess the prevalence of NAFLD/MAFLD stigma among both patients and physicians, and the beneficence of name change from NAFLD to MAFLD in Egypt to determine the factors leading to lifestyle modifications in NAFLD/MAFLD patients, thus improving patients' quality of life.
The questionnaire will target a convenience sample of NAFLD/NASH patients presenting to the Tropical Medicine Department clinics.
physicians treating NAFLD/NASH patients in Egypt
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients ≥ 18 years old diagnosed with NAFLD/ NASH and willing to complete the survey.
Other: Questionnaire
Physicians treating patients with NAFLD/NASH (hepatologists, gastroenterologists, endocrinologists, and internal medicine physicians).
Other: Questionnaire
A questionnaire in both digital and written forms in both Arabic and English versions.
Awareness of NAFLD/MAFLD stigma in Egypt
Using a questionnaire to assess awareness of stigma related to various diagnostic terms such as "fatty liver", "NAFLD", "MAFLD", and Metabolic dysfunction-associated steatotic liver disease "MASLD" in patients and in NAFLD/NASH treating physicians in Egypt.
Time frame: till August 2024
Perception of NAFLD/MAFLD stigma in Egypt
Using a questionnaire to assess perception of stigma related to various diagnostic terms such as "fatty liver", "NAFLD", "MAFLD", and "MASLD" in patients and in NAFLD/NASH treating physicians in Egypt.
Time frame: till August 2024
impact on quality of life
Using a questionnaire to understand the impact of NAFLD vs MAFLD stigma on the quality of life in Egyptian patients
Time frame: till August 2024
Motivations to lifestyle changes
Using a questionnaire to evaluate the motivation for lifestyle changes in Egyptian patients
Time frame: till August 2024
Barriers to lifestyle changes
Using a questionnaire to evaluate the barriers for lifestyle changes in Egyptian patients
Time frame: till August 2024
Started May 2024 (actual). Primary completion is estimated for Nov 2024, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →